Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
Gain Therapeutics, Inc. (Nasdaq: GANX) has announced that its Chief Medical Officer, Jonas Hannestad, M.D., Ph.D., will present at the Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference on October 17, 2024, in New York City. The presentation will focus on the company's clinical stage lead drug candidate GT-02287, which is being developed for the treatment of Parkinson's disease.
Dr. Hannestad's oral presentation, titled 'Brain-penetrant small molecule GT-02287 is well-tolerated in healthy volunteers, shows GCase target engagement, and achieves therapeutic exposures shown to modulate PD pathobiology in preclinical models,' will be part of the conference's first session, 'Progress in the Therapeutics Pipeline.' The presentation will include Phase 1 data for GT-02287 and recent preclinical findings.
The Parkinson's Disease Therapeutics Conference is the only global event focused exclusively on Parkinson's disease drug development, bringing together 300 research and clinical development professionals from academia and industry to showcase innovative research from MJFF's portfolio.
Gain Therapeutics, Inc. (Nasdaq: GANX) ha annunciato che il suo Chief Medical Officer, Jonas Hannestad, M.D., Ph.D., presenterà al 16° Congresso Annuale sui Trattamenti per la Malattia di Parkinson della Fondazione Michael J. Fox il 17 ottobre 2024, a New York City. La presentazione si concentrerà sul candidato principale per il trattamento clinico GT-02287, sviluppato per la cura della malattia di Parkinson.
La presentazione orale del Dr. Hannestad, intitolata 'La piccola molecola penetrante nel cervello GT-02287 è ben tollerata in volontari sani, mostra impegno verso il target GCase e raggiunge esposizioni terapeutiche dimostrate per modulare la patobiologia della PD in modelli preclinici,' farà parte della prima sessione del congresso, 'Progressi nel Pipeline dei Trattamenti.' La presentazione includerà dati di Fase 1 per GT-02287 e recenti scoperte precliniche.
Il Congresso sui Trattamenti per la Malattia di Parkinson è l'unico evento globale focalizzato esclusivamente sullo sviluppo di farmaci per la malattia di Parkinson, riunendo 300 professionisti della ricerca e dello sviluppo clinico provenienti da accademia e industria per mostrare ricerche innovative dal portafoglio di MJFF.
Gain Therapeutics, Inc. (Nasdaq: GANX) ha anunciado que su Director Médico, Jonas Hannestad, M.D., Ph.D., presentará en la 16ª Conferencia Anual sobre Terapias para la Enfermedad de Parkinson de la Fundación Michael J. Fox el 17 de octubre de 2024, en la ciudad de Nueva York. La presentación se centrará en el principal candidato de medicamento en etapa clínica GT-02287, que se está desarrollando para el tratamiento de la enfermedad de Parkinson.
La presentación oral del Dr. Hannestad, titulada 'La pequeña molécula penetrante en el cerebro GT-02287 es bien tolerada en voluntarios sanos, muestra compromiso con el objetivo GCase y alcanza exposiciones terapéuticas que modulan la patobiología de la PD en modelos preclínicos,' formará parte de la primera sesión de la conferencia, 'Avances en el Pipeline de Terapias.' La presentación incluirá datos de Fase 1 para GT-02287 y hallazgos preclínicos recientes.
La Conferencia sobre Terapias para la Enfermedad de Parkinson es el único evento global centrado exclusivamente en el desarrollo de medicamentos para la enfermedad de Parkinson, reuniendo a 300 profesionales de la investigación y el desarrollo clínico de la academia y la industria para mostrar investigaciones innovadoras del portafolio de MJFF.
Gain Therapeutics, Inc. (Nasdaq: GANX)는 치프 메디컬 오피서인 Jonas Hannestad, M.D., Ph.D.가 2024년 10월 17일 뉴욕에서 열리는 마이클 J. 폭스 재단 제16회 파킨슨병 치료 회의에 참석하여 발표할 것이라고 발표했습니다. 발표는 파킨슨병 치료를 위한 임상 개발 단계의 주요 약물 후보인 GT-02287에 초점을 맞출 것입니다.
Hannestad 박사의 구두 발표 제목은 '뇌 침투성 소분자 GT-02287은 건강한 자원봉사자에게 잘 견딜 수 있으며, GCase 표적 관여를 보여주고, 전임상 모델에서 PD 병리 생리를 조절하는 것으로 나타난 치료적 노출을 달성한다'이며, 회의의 첫 번째 세션인 '치료 파이프라인의 진전'의 일부가 될 것입니다. 발표에서는 GT-02287의 1상 데이터와 최근의 전임상 발견이 포함될 것입니다.
파킨슨병 치료 회의는 파킨슨병 약물 개발에 전적으로 집중된 유일한 글로벌 이벤트로, 학계와 산업에서 300명의 연구 및 임상 개발 전문가를 모아 MJFF 포트폴리오의 혁신적인 연구를 선보입니다.
Gain Therapeutics, Inc. (Nasdaq: GANX) a annoncé que son directeur médical, Jonas Hannestad, M.D., Ph.D., présentera lors de la 16e Conférence Annuelle sur les Thérapeutiques de la Maladie de Parkinson de la Fondation Michael J. Fox le 17 octobre 2024, à New York. La présentation se concentrera sur le candidat médicament principal en phase clinique GT-02287, qui est en cours de développement pour le traitement de la maladie de Parkinson.
La présentation orale du Dr. Hannestad, intitulée 'La petite molécule pénétrante dans le cerveau GT-02287 est bien tolérée chez des volontaires sains, montre un engagement envers la cible GCase et atteint des expositions thérapeutiques démontrées pour moduler la pathobiologie de la PD dans les modèles précliniques,' fera partie de la première session de la conférence, 'Progrès dans le Pipeline des Thérapeutiques.' La présentation inclura les données de Phase 1 pour GT-02287 ainsi que des découvertes précliniques récentes.
La Conférence sur les Thérapeutiques de la Maladie de Parkinson est le seul événement mondial exclusivement axé sur le développement de médicaments pour la maladie de Parkinson, rassemblant 300 professionnels de la recherche et du développement clinique issus du milieu académique et de l'industrie pour présenter des recherches innovantes du portefeuille de MJFF.
Gain Therapeutics, Inc. (Nasdaq: GANX) hat bekannt gegeben, dass sein Chief Medical Officer, Jonas Hannestad, M.D., Ph.D., am 16. jährlichen Parkinson-Therapiekongress der Michael J. Fox Stiftung am 17. Oktober 2024 in New York City präsentieren wird. Die Präsentation wird sich auf den fortgeschrittenen klinischen Medikamentenkandidaten GT-02287 konzentrieren, der zur Behandlung der Parkinson-Krankheit entwickelt wird.
Die mündliche Präsentation von Dr. Hannestad mit dem Titel 'Hirngängige kleine Moleküle GT-02287 sind gut verträglich bei gesunden Freiwilligen, zeigen GCase-Zielbindung und erreichen therapeutische Expositionen, die die PD-Pathobiologie in präklinischen Modellen modulieren' wird Teil der ersten Sitzung des Kongresses mit dem Titel 'Fortschritte in der Therapie-Pipeline' sein. Die Präsentation wird Daten der Phase 1 für GT-02287 sowie aktuelle präklinische Ergebnisse umfassen.
Der Parkinson-Therapiekongress ist die einzige globale Veranstaltung, die sich ausschließlich auf die Entwicklung von Medikamenten gegen die Parkinson-Krankheit konzentriert und 300 Fachleute aus Forschung und klinischer Entwicklung aus Wissenschaft und Industrie zusammenbringt, um innovative Forschung aus dem Portfolio von MJFF zu präsentieren.
- None.
- None.
BETHESDA, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Jonas Hannestad, M.D., Ph.D., Chief Medical Officer of Gain, will give an oral presentation on the Company’s clinical stage lead drug candidate GT-02287 at the Michael J. Fox Foundation’s (MJFF) 16th Annual Parkinson’s Disease Therapeutics Conference on October 17, 2024, in New York City.
The oral presentation titled, “Brain-penetrant small molecule GT-02287 is well-tolerated in healthy volunteers, shows GCase target engagement, and achieves therapeutic exposures shown to modulate PD pathobiology in preclinical models,” will be presented as part of the conference’s first session, “Progress in the Therapeutics Pipeline”.
“We look forward to presenting Phase 1 data for GT-02287, in development for the treatment of Parkinson’s disease, at the upcoming MJFF conference and appreciate the opportunity to contextualize these data with exciting preclinical data that have been generated recently for GT-02287. The Michael J. Fox Foundation shares our mission of bringing potentially life-changing treatments to people living with Parkinson’s disease,” commented Jonas Hannestad.
The Parkinson's Disease Therapeutics Conference (PDTC) is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. Each year, the PD Therapeutics Conference brings together 300 research and clinical development professionals from both academia and industry to showcase the most exciting and innovative research from MJFF's research portfolio. Novel advances in basic, translational, and clinical research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.
About GT-02287
Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an allosteric protein modulator that restores the function of the lysosomal protein enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, and improved motor function and cognitive performance. Additionally, GT-02287 significantly reduced plasma neurofilament light chain (NfL) levels, an emerging biomarker for neurodegeneration.
Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggests that GT-02287 may have the potential to slow or stop the progression of Parkinson’s disease.
Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement and modulation of GCase enzyme.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the offering and uncertainties related to the offerings and the use of proceeds from the offerings. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company’s Form 10-K for the year ended December 31, 2023 and Form 10-Q for the quarter ended June 30, 2024.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Apaar Jammu and Chuck Padala
ajammu@gaintherapeutics.com
chuck@lifesciadvisors.com
Media Contacts:
Russo Partners
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
FAQ
What will Gain Therapeutics (GANX) present at the Michael J. Fox Foundation conference?
When and where is the Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference?
Who will be presenting on behalf of Gain Therapeutics (GANX) at the conference?
What is the title of Gain Therapeutics' (GANX) presentation at the MJFF conference?
What is the significance of the Parkinson's Disease Therapeutics Conference?
